Maravai Lifesciences Holdings (MRVI) Cash from Operations Growth (3y) (2023 - 2026)

Maravai Lifesciences Holdings (MRVI) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -5.07%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 33.08%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -7.60%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Maravai Lifesciences Holdings 975.93 Mn 810.01 Mn 33.70 Mn -53.30%

Historic Data

Download Data
DateValue
Mar 31, 2026 -53.30%
Dec 31, 2025 -30.63%
Sep 30, 2025 -28.82%
Jun 30, 2025 -27.29%
Mar 31, 2025 -27.20%
Dec 31, 2024 -31.02%
Sep 30, 2024 -50.07%
Jun 30, 2024 -52.81%
Mar 31, 2024 -30.47%
Dec 31, 2023 -53.88%
Sep 30, 2023 -34.93%
Jun 30, 2023 18.23%
Mar 31, 2023 106.13%